0.26
-3.70%
Close of 6 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioNxt Solutions
Its shares trade on Canadian Securities Exchange under the ticker BNXT.CN. It has been listed since 6 August 2019. In the fiscal year to 31 December 2024, it reported revenue of C$26,985 and a net loss of C$5.3m. At that date it held total assets of C$569,355 and shareholders' equity of −C$7.9m.
BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The firm has research and development operations in North America and Europe, with an operational focus in Germany. The firm is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Aug 2019
- Website
- bionxt.com ↗
Leadership
Pay as last reported
- Mr. Hugh RogersChief Executive Officer, Director, since 2017C$189,305
- Mr. Wolfgang ProbstChief Financial Officer, Secretary, Director, since 2018C$177,816
- Mr. Thomas BeckertManaging Director, Vektor Pharma TF GmbHC$100,360
- Mr. Heinrich JehleManaging Director, 3a-diagnostics GmbHC$131,373
- Dr. Raimar LobenbergIndependent DirectorC$60,000
- Mr. Joseph MeagherIndependent Director, since 2021C$90,000
- Mr. David WaterhouseIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioNxt Solutions Inc. focuses on drug formulations and delivery systems for medical cannabis in Canada.
- 3a-diagnostics GmbH provides diagnostic products like the COVID-19 PCR Kit in Germany.
- R&D operations in North America and Europe support European market commercialization.
Weaknesses
- The company's business is limited to medical cannabis production and sales in Canada.
- Operational focus in Germany may face regulatory challenges for European market entry.
- Dependence on subsidiary 3a-diagnostics GmbH for diagnostic product development.
Opportunities
- Expansion of precision transdermal drug formulations in the European market.
- Growth in diagnostic screening tests for infectious diseases and oral health.
- Investment opportunities in new active pharmaceutical ingredients for neurological applications.
Threats
- Regulatory hurdles for medical cannabis in European markets.
- Competition from established pharmaceutical companies in Germany.
- Potential delays in regulatory approval for new drug formulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.